These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28566590)

  • 1. The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.
    Mori H; Okada Y; Tanaka Y
    Intern Med; 2017; 56(11):1301-1306. PubMed ID: 28566590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
    Kanazawa I; Yamaguchi T; Yano S; Yamamoto M; Yamauchi M; Kurioka S; Sugimoto T
    Osteoporos Int; 2010 Dec; 21(12):2013-8. PubMed ID: 20130841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
    Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
    Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus.
    van Lierop AH; Hamdy NA; van der Meer RW; Jonker JT; Lamb HJ; Rijzewijk LJ; Diamant M; Romijn JA; Smit JW; Papapoulos SE
    Eur J Endocrinol; 2012 Apr; 166(4):711-6. PubMed ID: 22267280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
    Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
    Kanazawa I; Yamamoto M; Yamaguchi T; Sugimoto T
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):362-5. PubMed ID: 21472665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
    Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
    Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial.
    Esteghamati A; Noshad S; Rabizadeh S; Ghavami M; Zandieh A; Nakhjavani M
    Regul Pept; 2013 Mar; 182():1-6. PubMed ID: 23328000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.